PCI Biotech: Main Results of the Full Phase I/II study of Amphinex(R)

6/24/2011 9:36:34 AM

OSLO, Norway--(BUSINESS WIRE)--PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today the main results of the completed Phase I/II study of the new component Amphinex® in the combination productPC-A11, where Amphinex is used in combination with the cytotoxic agent bleomycin. The primary objective of this dose escalation study is to assess the maximum tolerated dose of the new component Amphinex®. Secondary objectives include determination of the antitumour effect of the PC-A11 treatment, as well as pharmacokinetics of the Amphinex® component.

Read at BioSpace.com

Read Article at

Related Companies

News Categories

• BioSpace.com

• PCI Biotech

• Clinical - Phase I

• Clinical - Phase II

• Clinical - Phase I (World)

• Clinical - Phase II (World)